NFKB1 and head and neck squamous cell carcinoma: Bortezomib is a small-molecule proteasome inhibitor which affects multiple signaling pathways including NF-κB. Chung et al. treated 25 R/M SCCHN patients with bortezomib 1.6 mg/m2 and docetaxel 40 mg/m2 on days 1 and 8 of a 21-day cycle and observed a ORR and DCR of 5 and 52%, respectively.